What treatments are recommended for managing muscle tension (spasticity) in a patient with cerebral palsy?

Management of Muscle Tension (Spasticity) in Cerebral Palsy

Begin with a stepwise approach starting with physical therapy interventions (positioning, range of motion exercises, stretching, splinting), then escalate to botulinum toxin A injections for focal spasticity, oral medications (diazepam or tizanidine) for generalized spasticity, and reserve intrathecal baclofen or surgical options for severe refractory cases.

First-Line: Physical Therapy Interventions

Start all patients with CP-related spasticity on conservative physical modalities 1:

• Antispastic positioning performed several times daily
• Range of motion exercises to prevent contractures
• Passive stretching multiple times per day
• Splinting or serial casting for contractures interfering with function
• Surgical correction if contractures are fixed and limiting rehabilitation

These interventions should be implemented immediately as they prevent the most disabling complication—contractures that render limbs functionless and impair skin hygiene 1.

Second-Line: Botulinum Toxin A for Focal/Segmental Spasticity

For localized spasticity affecting specific muscle groups, botulinum toxin A is the established treatment of choice 2. This is Level A evidence—the strongest recommendation available.

• Proven effective for reducing spasticity in upper and lower extremities in children with CP
• Generally safe, though the FDA has investigated isolated cases of generalized weakness
• Consider for spasticity causing pain, poor skin hygiene, or decreased function 1, 3
• Multiple formulations (aboBoNT-A, incoBoNT-A, onaBoNT-A) are effective 3

Important caveat: While botulinum toxin A definitively reduces muscle tone, evidence for functional improvement is conflicting 2. Set realistic expectations with families.

Recent network meta-analysis data from 2025 supports combining botulinum toxin A with casting for enhanced spasticity reduction 4.

Third-Line: Oral Medications for Generalized Spasticity

When spasticity is widespread and warrants systemic treatment:

Diazepam (Level B - Should be considered)

• Probably effective for short-term spasticity reduction 2
• Major limitation: Deleterious effects on stroke recovery and significant sedation 1
• Use with extreme caution and only for brief periods
• Avoid benzodiazepines during active rehabilitation periods 1

Tizanidine (Level C - May be considered)

• Possibly effective for chronic spasticity 2
• Shown efficacy in chronic patients with improvement in spasticity and pain without loss of motor strength 1
• Better safety profile than diazepam

Other Oral Options

• Dantrolene and oral baclofen: Insufficient evidence in CP specifically, though FDA-approved for spasticity 1, 2
• Oral baclofen may cause significant sedation and has less impact compared to other conditions 1

Critical point: All oral medications reduce spasticity and pain but show no significant functional gains in most trials 1. Prioritize function over tone reduction alone.

Fourth-Line: Advanced Interventions for Refractory Cases

Intrathecal Baclofen (ITB)

• Consider for severe chronic spasticity unresponsive to other treatments 1, 5
• Particularly effective for spastic quadriparesis and generalized dystonia 5
• Delivers medication directly to spinal cord, avoiding systemic side effects
• Monitor for: infection risk and potential scoliosis progression 6

Neurosurgical Options

Selective Dorsal Rhizotomy (SDR)

• Best for spastic diplegia in ambulatory children (GMFCS II-III) 6
• Offers sustained spasticity reduction
• Combined dorsal-ventral rhizotomy shows promise for mixed presentations 6

Peripheral Neurectomies

• Targeted approach for focal spasticity 6
• Provides sustained improvements in muscle tone and walking speed

Deep Brain Stimulation (DBS)

• Emerging option for dystonia-predominant CP 5, 6
• Targets globus pallidus internus
• Younger patients show greater improvement
• Cerebellar DBS under investigation for spasticity 6

Important surgical caveat: Procedures like selective dorsal rhizotomy carry significant risks including operative complications and unintended spinal cord damage 1.

Emerging Therapies with Supporting Evidence

Recent 2025 network meta-analysis identified additional effective modalities 4:

• Biofeedback: Significantly reduced spasticity (SMD -3.29)
• Transcranial direct current stimulation: Effective for spasticity reduction
• Extracorporeal shockwave therapy: Works across various spasticity levels
• Acupuncture: Demonstrated consistent efficacy across spasticity, gross motor function, daily living, and walking (SMDs 0.72-2.04)
• Hippotherapy and gaming: Improved gross motor function (SMD 0.91-6.75)
• Whole-body vibration: Reduced spasticity and improved function

Treatments to Avoid

• Phenol/alcohol injections: Insufficient data in CP population 2
• Botulinum toxin type B: No studies meeting criteria available 2
• Benzodiazepines during active rehabilitation: Impair recovery 1

Clinical Decision Algorithm

1. All patients: Start physical therapy interventions immediately
2. Focal spasticity (specific muscle groups): Add botulinum toxin A injections
3. Generalized mild-moderate spasticity: Consider tizanidine first-line, diazepam only for short-term use
4. Severe generalized spasticity failing oral medications: Escalate to intrathecal baclofen
5. Ambulatory spastic diplegia: Consider selective dorsal rhizotomy
6. Dystonia-predominant: Consider deep brain stimulation
7. Adjunctive therapies: Add biofeedback, acupuncture, or extracorporeal shockwave therapy based on availability and patient tolerance

Key principle: Early treatment is essential to prevent contractures 1. The goal is not just tone reduction but preservation of function, prevention of pain, maintenance of skin hygiene, and optimization of rehabilitation potential.